KRAS and non-small cell lung carcinoma: According to the inclusion and exclusion criteria, 115 KRAS mutant NSCLC patients received chemotherapy regimen and 65 patients received immunotherapy as first-line treatment were included, the specific process is shown in Fig. 1.